Ardena’s customer Revolo starts new clinical trials

Nov. 2021

We are pleased to share that Revolo Biotherapeutics has received MHRA Approval for Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in the United Kingdom. Congratulations to Revolo Biotherapeutics on this important milestone.
At Ardena, we value our customer relationship with Revolo Therapeutics and we look forward to future opportunities for collaboration.
Read Revolo’s full press release here